Press release
Investigation announced for Investors in shares of Amgen Inc. (NASDAQ: AMGN) over potential Wrongdoing
An investigation on behalf of investors in Amgen Inc. (NASDAQ: AMGN) shares over potential wrongdoing at Amgen Inc. was announced.
Investors who purchased shares of Amgen Inc. (NASDAQ: AMGN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Amgen Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Thousand Oak, CA based Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Amgen Inc. reported that its annual Total Revenue rose from over $25.42 billion in 2020 to over $25.97 billion in 2021, and that its Net Income declined from over $7.26 billion in 2020 to over $5.89 billion in 2021.
On April 27, 2022, Amgen Inc disclosed in its first quarter 2022 earnings release that "[o]n April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service ('IRS')] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company's entities in the United States and the U.S. territory of Puerto Rico" which "seeks to increase Amgen's U.S. taxable income for the 2013-2015 period by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest." Amgen Inc also disclosed that the IRS "notice proposes penalties of approximately $2 billion."
Shares of Amgen Inc. (NASDAQ: AMGN) declined $258.39 per share on April 21, 2022, to $231.15 per share on April 28, 2022.
Those who purchased shares of Amgen Inc. (NASDAQ: AMGN) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Amgen Inc. (NASDAQ: AMGN) over potential Wrongdoing here
News-ID: 2668452 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Amgen
Biopharmaceutical Market 2023 | Emerging Technologies, Business Trends | Amgen I …
The strategy analysis on Global Biopharmaceutical Market gives insights of market size, trends, share, growth, development plans, Investment Plan, cost structure and driver's analysis. With precise data covering all key aspects of the existing market, this report offers existing data of leading manufacturers. The Biopharmaceutical Market report covers marketing channels and market positioning to potential growth strategies, providing in-depth analysis for new competitors or existing competitors in the Biopharmaceutical Industry.
The…
Oncology Biosimilars Market Analysis 2020: Pfizer, Amgen, Allergan
The rising technology in Oncology Biosimilars Market is also depicted in this research report. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.
This is the most recent report that includes the effects of COVID-19 on the functioning of the market. It is well known that some changes, for the worse, were managed by the pandemic…
Global Erythropoietin Market 2019 - Amgen, Johnson & Johnson, Roche
This new report by Eon Market Research, titled “Global Erythropoietin Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Erythropoietin industry at a global as well as regional and country level. Key facts analyzed in this report include the Erythropoietin market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive…
Biotechnology Market Competitive Landscape with Amgen Inc, Amgen Inc, Celgene, M …
Biotechnology Market to exceed USD 775 billion by 2024 as per a new research report.
Favorable government initiative and growing demand for synthetic biology will drive the biotechnology industry growth over the forecast timeframe. Also rising demand for agro-based products should fuel global biotechnology market growth.
Decreasing cost of DNA sequencing from last couple of decades owing to the advances in the field of genomics will stimulate the global biotechnology market. Furthermore,…
Ticagrelor Market 2027 Top Key Players are AstraZeneca, Eli Lilly, Boehringer, I …
MRFR is the Leading Brand in The Research Company who Recently Published Ticagrelor Market Research Reports which includes Study of growth, Regional Analysis, Top Industry Players Formation, Major Drivers, Upcoming Trends and Forecast to 2027.
Global Ticagrelor Market - Overview
Ticagrelor is an antiplatelet drug which is a member of a section of pharmaceuticals which tackle the problem of platelet aggression. The Global Ticagrelor Market is expected to grow at a healthy…
2018 Biologic Drugs Market Future by Manufacturers- Roche, Abbott Laboratories, …
Download PDF Sample @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1656420
The Global Biologic Drugs Industry Report 2018 is a professional and in-depth study on the current state of the Biologic Drugs Market.
Key Companies Analysis- Roche, Abbott Laboratories, Johnson & Johnson, Merck & Co., Pfizer, Amgen, Sanofi, Novartis, Eli Lilly, Amgen
Complete report on Biologic Drugs market spread across 94 pages, profiling 10 companies and supported with…
